The IDO1-specific inhibitor 1-methyltryptophan has been shown to significantly inhibit IDO1 activity, and the effects of 1-methyltryptophan in enhancing T-cell responses against tumor antigens, allograft antigens, and autoantigens in vivo have been validated (24, 25). The gene discussed is IDO1; the disease is neoplasm.